Can Roche Make A Case For Avastin In Brain Cancer Based On Quality Of Life?

With two trials failing to show a survival advantage in first-line glioblastoma, the company must go to FDA with a progression-free survival benefit and quality-of-life data from one trial to support its accelerated approval in the advanced setting.